BNP Paribas upgrades Novonesis after 20% sector underperformance

BNP Paribas upgraded Novonesis to “neutral” from “underperform” after a ~20% YTD underperformance, noting valuation pullback to ~24x projected 2027 earnings (down from ~40% premium end-2025). The broker targets 415 DKK vs a 425.8 DKK close (about 3% downside) and highlights potential for a 2Q guidance upgrade, with 2026 estimates broadly in line with consensus. It expects improving ingredients sentiment on improving volumes and moderating oil prices, while cautioning the bar for 2Q execution has risen as input costs into H2 remain a “manageable” risk.

Analysis

The market setup favors dispersion over outright sector beta. Easing oil and benign 2026 raw-material inflation mostly protect gross margins; they do not by themselves create durable top-line acceleration, so the names that can pair stable volume with a credible guide-up are the ones likely to earn multiple expansion. That makes the lower-quality rerating candidates less attractive than the companies with clearer revision paths: KRYAY/KRYPF, SXT, and SYIEY should have more torque to a modest Q2 beat than a premium-valuation name still needing proof of long-term growth.

For BNPQY, the key risk is that the stock has already moved closer to fair value on a forward basis while the fundamental debate remains unresolved. A neutral upgrade can support a short-term catch-up trade, but if Q2 only confirms consensus instead of raising 2026/2027 assumptions, the higher multiple can compress again within 1-3 months. The market is likely to reward evidence of volume resilience more than cost relief, so this is a proof story, not a macro story.

Contrarian view: the ingredient basket may be underpricing how much of the easy sentiment recovery is already reflected after the recent rebound. If end-demand is merely stable rather than improving, the next rerate could stall once investors recognize that lower input costs are offset by weaker pricing power in H2. The longer-dated watch item is 2027 fertilizer and El Niño risk, but the near-term falsifier is any earnings print or guidance that fails to show incremental margin upside versus consensus.

Key Decisions for Investors

• Long KRYAY/KRYPF into Q2 results; target a 6-10% relative upside if management confirms volume resilience and even modest 2026 margin upside. Cut if the company sounds cautious on demand elasticity or passes on less than expected pricing.
• Pair trade: long SXT / short BNPQY for the next 4-8 weeks. Thesis is that SXT has a cleaner path to an upgrade on execution and margin stability, while BNPQY still trades with a premium that leaves limited upside unless growth re-accelerates.
• Add SYIEY on pullbacks ahead of earnings as the highest-quality expression of the sector rerating. Expect a 1-2 turn multiple support move if sequential organic momentum is confirmed; invalidate on any H2 volume slowdown.
• Use BNPQY only as a tactical bounce candidate, not a core long. If the stock fails to reclaim its recent relative-performance gap versus the basket after Q2, treat that as evidence the upgrade was already in the price.